Despite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.
See The Scrip 100: Changes At The Top Of The Leaderboard for detailed commentary and analysis of the Scrip 100 leaders.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.
Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.
